“The Association of the British Pharmaceutical Industry (ABPI) welcomes NHS England’s Medicines Optimisation Prototype Dashboard, which is a step in the right direction in helping the local NHS explore how well-placed they are to optimise the use of medicines for patients in their area. It should also encourage the NHS to engage and adopt the principles described in the medicines optimisation agenda. Supporting patients to use medicines more appropriately will not only deliver better patient care, it will also provide cost savings for the NHS by improving NHS productivity by reducing the need for longer term, more expensive treatment and helping to shift care from hospitals into the community.
“We fully support NHS England’s shift in focus from looking solely at the spend on medicines in isolation towards the value of medicines and having a better understanding of medicines and the outcomes derived from using them. Medicines optimisation recognises that we can raise levels of patient care in the NHS through investment in, and better use of, medicines. It is key to ensuring that the right patients get the right medicines at the right time.
“Better access to innovative medicines for patients will support improved health outcomes and help address prescribing variations across the country. The ABPI is currently in discussion with both the Department of Health and NHS England on how best to ensure that the Pharmaceutical Price Regulation Scheme (PPRS) delivers better access to innovative medicines for patients. In looking at the best way to achieve this, we need to see aligned incentives, to ensure the most appropriate and effective use of medicines aligned to the four Principles of Medicines Optimisation."
“We are pleased to note that this prototype dashboard is not being presented as the final product as there is more work to be done to ensure that this tool works in the best interests of patients. The ABPI will work closely with NHS England to develop the dashboard further to help ensure that the intrinsic value of medicines to improve healthcare outcomes for patients is realised.”
Notes to editor
About the ABPI
The ABPI represents innovative research-based biopharmaceutical companies, large, medium and small, leading an exciting new era of biosciences in the UK.
Our industry, a major contributor to the economy of the UK, brings life-saving and life-enhancing medicines to patients. Our members supply 90 per cent of all medicines used by the NHS, and are researching and developing over two-thirds of the current medicines pipeline, ensuring that the UK remains at the forefront of helping patients prevent and overcome diseases.
The ABPI is recognised by government as the industry body negotiating on behalf of the branded pharmaceutical industry, for statutory consultation requirements including the pricing scheme for medicines in the UK.
ABPI Press Office
Telephone: +44 (0) 20 7747 1410 or +44 (0) 20 7747 1441
Mobile: +44 (0) 7850 312064 or +44 (0) 7808 641811